Related Experiment Videos
Chlorpromazine versus clotiapine for schizophrenia
Shahrzad Mazhari1, Saeed Esmailian2, Armita Shah-Esmaeili3
1Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.
The Cochrane Database of Systematic Reviews
|April 8, 2017
Summary
This review found limited evidence comparing chlorpromazine and clotiapine for schizophrenia. While clotiapine showed a potential benefit in mental state, data quality was very low, and comparative effectiveness remains unclear.
Area of Science:
- Psychiatry and Mental Health
- Pharmacology
- Clinical Trials
Background:
- Schizophrenia is a severe mental disorder impacting perception, thought, and behavior.
- Chlorpromazine and clotiapine are antipsychotic medications used in schizophrenia treatment.
Purpose of the Study:
- To compare the clinical effects, safety, and cost-effectiveness of chlorpromazine versus clotiapine in adults with schizophrenia.
- To synthesize evidence from randomized clinical trials on these two antipsychotics.
Main Methods:
- Systematic search of the Cochrane Schizophrenia's Trials Register and other databases.
- Inclusion of four randomized clinical trials (RCTs) with 276 participants.
- Data extraction and analysis using risk ratios and mean differences with random-effects models.
Main Results:
- Limited data available, with studies published between 1974 and 2003 and short follow-up periods (under six months).
- One RCT suggested clotiapine may offer greater improvement in mental state (PANSS total scores), but evidence quality was very low.
- No significant differences observed in negative symptoms, incidence of dyskinesia, or early study withdrawal between the two drugs.
- Key outcomes like clinically important changes in global/mental state and cost of care were not adequately reported.
Conclusions:
- The comparative effectiveness of chlorpromazine versus clotiapine for schizophrenia remains largely undetermined due to insufficient and low-quality evidence.
- Results suggest similar adverse effect profiles, but methodological limitations hinder firm conclusions.
- Further high-quality research is needed to clarify the relative benefits and risks of these antipsychotics.